Best Peptides for Weight Loss: What the Community Actually Uses (2026)
The peptides most used for weight loss are the GLP-1 class — tirzepatide and semaglutide lead, followed by the experimental triple-agonist retatrutide — but "most used" is not the same as "best for you," and only two of them are actually FDA-approved. This page answers the real question two ways at once: what the ProtocolPlus community reaches for, and what the evidence says about each option.
Most "best peptides for weight loss" lists rank compounds by an author's opinion. We do it differently. The headline ranking below comes from first-party usage data — what ~11,400 ProtocolPlus users pursuing weight loss actually track — and we keep the editorial "why" (evidence, safety, cost, speed) clearly separate as context, never as the ranking. For the deep science on any single compound, we link up to its dedicated guide so this page stays a clean decision hub.
Key Takeaways
- What the community uses (not an efficacy ranking): across ~11,400 ProtocolPlus users pursuing weight loss, the top three are tirzepatide (32%), semaglutide (26%), and the investigational retatrutide (16%) — together roughly three in four (ProtocolPlus app data).
- What the community uses ≠ what is proven best. Usage reflects availability, cost, and hype as much as evidence. Read the ranking as a popularity signal, then weigh it against the evidence tiers below.
- Three are now FDA-approved for weight loss: semaglutide (Wegovy), tirzepatide (Zepbound), and oral orforglipron (Foundayo, 2026). Retatrutide and cagrilintide are investigational; AOD-9604 and 5-amino-1MQ are research-grade.
- Trial weight loss, best evidence per compound: semaglutide ~14.9% (STEP 1, 68 wk), tirzepatide ~22.5% (SURMOUNT-1, 15 mg, 72 wk), retatrutide ~24.2% (Phase 2, 12 mg, 48 wk). Trial averages, not typical real-world results.
- Two "fat-loss" peptides have no human efficacy: AOD-9604 failed to beat placebo in a Phase 2b trial, and 5-amino-1MQ has mouse data only. Popular in some corners, unproven in people.
- Want needle-free or prescription-only? Filter the selector above: prescription-only now keeps the three approved options (Zepbound, Wegovy, and oral Foundayo/orforglipron); oral-only leaves orforglipron (Foundayo, FDA-approved) and 5-amino-1MQ (mouse data only).
What peptides does the ProtocolPlus community use for weight loss?
Across ~11,400 ProtocolPlus users pursuing weight loss, tirzepatide is the most-tracked peptide (32%), followed by semaglutide (26%) and the experimental triple-agonist retatrutide (16%) — together about three in four users. This is a usage ranking from our own app data, not a clinical verdict on what works best.
The pattern is intuitive once you see it. The two GLP-1 drugs with weight-loss approvals dominate because they are the easiest to get through a clinic, while retatrutide — still investigational — already pulls a fast-growing experimental cohort because its early trial numbers are the highest in the field. After the top three, usage drops into a long tail: GLP-1 microdose blends (9%), cagrilintide (6%), oral orforglipron (5%), and a small legacy following for AOD-9604 and 5-amino-1MQ (3% each).
These shares come only from our community-usage dataset and describe behavior, not efficacy. A compound can be widely used and weakly evidenced at the same time — AOD-9604 is exactly that case. Read this chart as "what people in the community reach for," then cross-check it against the evidence tiers in the decision matrix further down.
Citation capsule. Among ~11,400 ProtocolPlus users who logged weight loss as a goal, the most-tracked compounds were tirzepatide (32%, 3,648 users), semaglutide (26%, 2,964), and retatrutide (16%, 1,824). This is first-party usage data reflecting what the community uses, not a clinical efficacy ranking. Source: ProtocolPlus app data (goals/weight-loss.json), 2026.
The community's top 3 picks (by usage)
The community's three most-used weight-loss peptides are tirzepatide, semaglutide, and retatrutide — two FDA-approved GLP-1 drugs and one investigational triple-agonist. Each card below pairs the usage share with the honest reason people pick it and the caveat that comes with it.
These three account for roughly 74% of weight-loss usage in our cohort. The split tracks a simple logic: accessibility plus the strongest numbers. The two approved drugs are reachable through a clinic; retatrutide is not approved but draws an experimental crowd chasing the highest trial weight loss reported so far.
Tirzepatide
Why people pick it: a dual GIP/GLP-1 agonist with the largest community cohort and the strongest approved-drug trial numbers (SURMOUNT-1).
Honest caveat: GI side effects on titration; research-grade vials are unregulated; brand cost is high without coverage.
Semaglutide
Why people pick it: the most-studied GLP-1 for weight loss (the STEP trials), approved as Wegovy, and the household name that brought this whole category mainstream.
Honest caveat: slower titration; weekly injection; brand cost is high without coverage; smaller average loss than tirzepatide head-to-head.
Retatrutide
Why people pick it: a triple agonist with the highest Phase-2 weight-loss figures so far; a fast-growing experimental cohort chasing the biggest numbers.
Honest caveat: investigational — not approved; only research-grade supply; longer-term safety still unknown.
The long tail (ranks 4–8): the remaining ~26% of usage spreads across GLP-1 microdose blends (9%), cagrilintide (6%), oral orforglipron (5%), and the two research-grade outliers AOD-9604 and 5-amino-1MQ (3% each). The blends and cagrilintide are workarounds and combinations of the leaders; orforglipron is the FDA-approved "no needles" oral option (Foundayo); the last two have a following but no human efficacy. Each gets a mini-section below.
How do weight-loss peptides actually work?
The peptides that drive real weight loss almost all work the same way — they mimic gut hormones (GLP-1, GIP, and sometimes glucagon or amylin) that turn down appetite, slow how fast the stomach empties, and steady blood sugar, so you eat less without forcing willpower. The differences between the leaders are mostly about how many of those hormone receptors a single molecule hits.
This shared mechanism is why the usage ranking is so top-heavy with the GLP-1 class and why the "fat burner" peptides further down the list underperform. Semaglutide activates one receptor (GLP-1). Tirzepatide adds a second (GIP). Retatrutide adds a third (glucagon), which can also nudge energy expenditure upward — the leading explanation for its larger trial numbers; we unpack this class in triple-agonist "GLP-3" compounds. Cagrilintide works on a different appetite pathway (amylin), which is why it is usually paired with a GLP-1 rather than used alone. How long each molecule stays active also differs widely, a point we cover in GLP-1 pharmacokinetics.
The two compounds whose usage outruns their evidence work on entirely different premises that have not held up in people. AOD-9604 is a growth-hormone fragment meant to trigger fat breakdown, and 5-amino-1MQ blocks an enzyme (NNMT) tied to fat-cell metabolism — promising on paper, but neither has shown human weight loss. The receptor-by-receptor science for any single compound lives on its hub; for the foundations of how injectable peptides act in the body, see how peptides work.
Citation capsule. The evidence-backed weight-loss peptides are incretin-hormone mimics: semaglutide is a GLP-1 receptor agonist, tirzepatide a dual GIP/GLP-1 agonist, and retatrutide a triple GLP-1/GIP/glucagon agonist. They reduce appetite, slow gastric emptying, and improve glycemic control; the triple agonist adds glucagon-driven energy expenditure. Source: NEJM (STEP 1, 2021; SURMOUNT-1, 2022; retatrutide Phase 2, 2023).
Which weight-loss peptide is right for you?
The right pick depends on three filters most people can answer in a sentence: do you want a prescription drug or research-grade, injectable or oral, and how much unproven risk you will accept. The decision matrix below sets the eight candidates against the dimensions that actually decide it.
This table is the "why" behind the usage ranking — editorial context, not the headline. The selector quiz at the top runs the same logic interactively: choosing prescription-only collapses the list to the two approved drugs (Zepbound and Wegovy), and choosing oral-only leaves orforglipron and 5-amino-1MQ. Use it to narrow, then read the evidence column honestly.
| Compound | Route | Rx status (2026) | Best trial weight loss | Evidence tier | Picked when… |
|---|---|---|---|---|---|
| Tirzepatide | Injectable | FDA-approved (Zepbound) | ~22.5% (SURMOUNT-1, 15 mg, 72 wk) | Strong, approved | You want the biggest approved result |
| Semaglutide | Injectable | FDA-approved (Wegovy) | ~14.9% (STEP 1, 68 wk) | Strong, approved | You want the most-studied approved option |
| Retatrutide | Injectable | Investigational | ~24.2% (Phase 2, 12 mg, 48 wk) | Promising, not approved | You accept research-grade risk for the highest numbers |
| Cagrilintide | Injectable | Investigational | ~22.7% combined (CagriSema, 68 wk) | Combination-studied | You are stacking amylin with a GLP-1 |
| Orforglipron | Oral | FDA-approved (Foundayo) | ~12.4% (Phase 3 ATTAIN-1, 72 wk) | Approved, oral | Needles are a dealbreaker |
| GLP-1 blends | Injectable | Research-grade | No blend-level trial data | Weak (no blend data) | You want to soften cost or side effects (trade-off: no dose control) |
| AOD-9604 | Injectable | Research-grade | Failed to beat placebo (Phase 2b) | Failed in humans | (Legacy following only) |
| 5-Amino-1MQ | Oral | Research-grade | None (mouse data only) | Preclinical only | (Niche oral following only) |
How do the leading weight-loss peptides actually compare on trial results?
On controlled-trial weight loss, the rough ladder runs semaglutide (~15%) → tirzepatide (~22.5%) → retatrutide (~24.2%), with oral orforglipron lower (~12.4%) and the research-grade peptides effectively at zero proven effect. These are averages from separate trials in different populations, so treat the ladder as directional, not a head-to-head.
The numbers are real and well-sourced, but the comparison has a catch worth stating plainly: more receptors and bigger numbers also mean less regulatory certainty. Semaglutide and tirzepatide have FDA approval and years of real-world data; retatrutide has the steepest curve but no approval; and AOD-9604 and 5-amino-1MQ have following without efficacy. The third chart visualizes exactly this trade-off — effect size against evidence tier — so the popular-but-unproven options land where they belong.
In 2021, the STEP 1 trial (semaglutide 2.4 mg) reported a mean 14.9% body-weight reduction at 68 weeks (NEJM, Wilding et al., 2021, retrieved 2026-06-16). In 2022, SURMOUNT-1 (tirzepatide) reported up to 22.5% at 72 weeks on the 15 mg dose (Eli Lilly / NEJM, Jastreboff et al., 2022, retrieved 2026-06-16). In 2023, the retatrutide Phase 2 trial reported up to 24.2% at 48 weeks on 12 mg (NEJM, Jastreboff et al., 2023, retrieved 2026-06-16). For the full head-to-head on the two approved leaders — cost, side effects, switching — see our semaglutide vs tirzepatide comparison.
Each candidate, briefly (with where to go deeper)
Here is each of the eight compounds in two-to-four sentences — enough to place it, with a link up to its full guide for the science. This page owns the "which one, and why" decision; the mechanism, dosing, and side-effect depth live on each compound's hub.
Tirzepatide (Zepbound / Mounjaro)
A dual GIP/GLP-1 receptor agonist and the community's most-used weight-loss peptide. It is FDA-approved as Zepbound (and sold as Mounjaro for type 2 diabetes) and produced up to ~22.5% mean weight loss in SURMOUNT-1, the largest result among approved drugs. Full mechanism, dosing, and side effects: tirzepatide complete guide.
Semaglutide (Wegovy / Ozempic)
The single-receptor GLP-1 agonist that made this category mainstream, FDA-approved for weight loss as Wegovy. STEP 1 reported ~14.9% mean loss — strong, well-studied, slightly below tirzepatide head-to-head. Deeper dive: semaglutide complete guide, and the head-to-head: semaglutide vs tirzepatide.
Retatrutide
An investigational triple agonist (GLP-1 + GIP + glucagon) with the highest trial weight loss reported so far (~24.2% in Phase 2). It is not approved, available only as a research chemical, and its long-term safety is still unknown — which is exactly why usage trails the two approved leaders. Full guide: retatrutide complete guide.
Cagrilintide
A long-acting amylin analog, usually studied in combination with semaglutide (the CagriSema pairing reported ~22.7% combined). It is investigational and rarely used alone; people who track it are typically stacking it for added appetite control. More: cagrilintide guide.
Orforglipron
An oral, non-peptide GLP-1, now FDA-approved as Foundayo (2026) for weight management — the pick when needles are a dealbreaker, with ~12.4% reported in Phase 3 ATTAIN-1. Approved for weight only (its diabetes use is still under review). More: orforglipron guide.
GLP-1 microdose blends
Fixed-ratio research-grade blends people use to soften side effects or stretch cost. There is no trial data on the blends themselves, and the fixed ratio removes dose control — a convenience trade-off, not an evidence-based choice. Background: guide to peptide blends.
AOD-9604
A fragment of human growth hormone (also called fragment 176-191) marketed for fat loss, kept alive by a small legacy following. Its Phase 2b weight-loss trial failed to beat placebo, and its fat-loss mechanism is unproven in humans. The honest verdict and history: AOD-9604 guide.
5-Amino-1MQ
An oral NNMT-inhibitor (not technically a peptide) with a niche fat-loss following. The evidence is mouse data only — there is no human efficacy data at all, so any weight-loss claim is extrapolation from rodents. More: 5-amino-1MQ guide.
What the community uses is not what is proven best
Treat the usage ranking as a popularity signal shaped by availability, cost, and hype — not as evidence of what works best or safest. The clearest proof is that AOD-9604, which failed its weight-loss trial, still pulls more community usage than approval-track options simply because it is cheap and easy to buy.
Three honest framings sit on top of every number on this page. First, three are now FDA-approved for weight management: semaglutide (Wegovy), tirzepatide (Zepbound), and oral orforglipron (Foundayo, approved 2026); retatrutide and cagrilintide remain investigational; AOD-9604 and 5-amino-1MQ are research-only with failed or absent human efficacy. Second, trial averages are a ceiling, not a promise — real-world results depend on the dose reached, how long someone stays on, tolerability, and lifestyle, and across the GLP-1 class stopping is associated with weight regain. Third, research-grade vials carry quality risk — unknown potency, purity, and sterility — that no usage statistic captures. For grounded expectations, see peptides before and after, and before sourcing anything, how to vet peptide quality and are peptides legal.
Our take: The most useful way to read this page is as two layers. The usage chart tells you what real people are doing; the evidence columns tell you what the data supports. When those two agree — as they do for tirzepatide and semaglutide — that is the strongest signal. When they diverge — as with AOD-9604 — trust the evidence, not the crowd.
What weight loss is realistic, and how fast?
Expect appetite to drop within the first few weeks but real weight loss to build over months, and expect your own result to land below the trial headlines, which are averages from the highest doses sustained for a year or more. The big percentages are a ceiling, not a promise.
A few grounding facts make those numbers usable. The STEP 1 (~14.9%), SURMOUNT-1 (~22.5%), and retatrutide Phase 2 (~24.2%) figures were all measured at 48 to 72 weeks, on people who reached and tolerated the top doses with structured support — not at week eight, and not at a starting dose. Results scale with the dose reached and how long someone stays on, and individual outcomes vary widely with metabolism, diet, and activity. The class also shares a hard truth on the back end: across GLP-1 drugs, stopping is associated with meaningful weight regain, which is why these are studied as long-term, not short-term, tools.
The practical read for choosing a compound: a realistic difference between, say, semaglutide and tirzepatide is a handful of percentage points of average loss, not a transformation gap — so route, cost, tolerability, and access often matter more than chasing the single highest trial number. For grounded before-and-after context and how to read transformation claims, see peptides before and after.
Our take: The most common mistake is anchoring to the 24% headline and treating anything less as failure. In practice, reaching and holding a tolerable dose for many months is what produces results — the compound matters less than the consistency, the support, and a clinician keeping it safe.
Who should be cautious, and who should not use these
Weight-loss peptides are not for everyone, and the research-grade ones are not for anyone outside a clinician's oversight. GLP-1-class drugs carry real contraindications, and the investigational and research-only compounds add unknown-risk on top.
A few hard lines worth stating: the GLP-1 class is generally contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2, and is not used in pregnancy or breastfeeding (FDA Wegovy prescribing information, retrieved 2026-06-16). Anyone with a history of pancreatitis, gallbladder disease, or significant GI conditions needs medical guidance before starting. And for the investigational or research-only compounds, the responsible answer is simpler: there is no validated safe-use protocol, so they belong in a trial or under a clinician, not in a self-directed cycle. None of this page is a substitute for that conversation.
Frequently Asked Questions
The bottom line
If you came here for a single "best peptide for weight loss," the honest answer is layered. The community's most-used options are tirzepatide and semaglutide, and they are also the two with FDA approval and the strongest real-world track record — when the crowd and the evidence agree, that is the signal worth trusting. Retatrutide posts the biggest trial numbers but remains investigational and research-grade only, a higher-risk bet for people chasing the steepest curve.
The compounds to be most skeptical of are the ones whose usage outruns their evidence: AOD-9604 failed its trial, and 5-amino-1MQ has never been tested in humans. The selector at the top of this page narrows the field to your constraints — prescription or research-grade, injectable or oral — but the final call belongs with a clinician who knows your health history. From here, the natural next reads are the semaglutide vs tirzepatide head-to-head, the retatrutide guide, and how to vet peptide quality.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine, 2021. DOI 10.1056/NEJMoa2032183. Retrieved 2026-06-16. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine, 2022. Eli Lilly investor release. Retrieved 2026-06-16. https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine
- Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial." New England Journal of Medicine, 2023. DOI 10.1056/NEJMoa2301972. Retrieved 2026-06-16. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- Novo Nordisk / PR Newswire. "CagriSema (2.4 mg / 2.4 mg) demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM." 2025. Retrieved 2026-06-16. https://www.prnewswire.com/news-releases/cagrisema-2-4-mg--2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-redefine-1--published-in-nejm-302487770.html
- Eli Lilly and Company. "Lilly's oral GLP-1 orforglipron — Phase 2 results published in the New England Journal of Medicine" and ATTAIN-1 Phase 3 topline. 2024–2025. Retrieved 2026-06-16. https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-results-published-new-england-journal-medicine
- Stanford SC, et al. (review). "AOD-9604 and obesity pharmacotherapy." PMC3584306. Retrieved 2026-06-16. https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/
- Neelakantan H, et al. "Selective and membrane-permeable small-molecule inhibitors of NNMT (5-amino-1MQ) reduce body weight in diet-induced obese mice." Scientific Reports, 2021. Retrieved 2026-06-16. https://www.nature.com/articles/s41598-021-03670-5
- U.S. Food & Drug Administration. "Wegovy (semaglutide) injection — Prescribing Information." 2021. Retrieved 2026-06-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
- ProtocolPlus. "Community goal-usage data: weight loss" (goals/weight-loss.json). First-party app data, 2026. n ≈ 11,400 users pursuing weight loss. Usage signal, not a clinical efficacy ranking.